Etid klinik pou Sipwa nan Idaho
19 etid pou Sipwa ap chèche patisipan nan sit nan Idaho.
Vil nan Idaho
Tèks ofisyèl etid la (Anglè)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Elite Clinical Trials - Blackfoot /ID# 282042, Blackfoot
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Oct 1, 2026 · NCT07752979A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- Solaris Clinical Research, Meridian
Ap rekriteFaz 3
Laj 8 a 18 · Tout sèks · Mizajou Sep 30, 2026 · NCT07253285A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Family First Medical Center, Idaho Falls
- Solaris Clinical Research, Meridian
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07794579Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Grand Teton Research Group, Idaho Falls
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937099Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Grand Teton Research Group, Idaho Falls
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937086Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Velocity Clinical Research - Boise, Meridian
Ap rekriteFaz 3
Laj 45 a 99 · Tout sèks · Mizajou Sep 22, 2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Family First Medical Center, Idaho Falls
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07392190A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Medical Research Partners, Ammon
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 22, 2026 · NCT07589608Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Medical Research Partners, Ammon
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07353931A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Boise
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Boise
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743450A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Elite Clinical Trials, Blackfoot
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Elite Clinical Trials, Rexburg
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 14, 2026 · NCT06897475A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Meridian
Ap rekriteFaz 3Volontè an sante akeyi
Laj 18 a 79 · Tout sèks · Mizajou Sep 11, 2026 · NCT07654374A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Medical Research Partners, Ammon
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 8, 2026 · NCT06143956Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Solaris Clinical Research, Meridian
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07684235Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Solaris Clinical Research, Meridian
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Aug 27, 2026 · NCT07575399Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Meridian
- ACCOMPLISH-1 Research Site, Rexburg
Ap rekriteFaz 3
Laj 18 a 79 · Tout sèks · Mizajou Aug 10, 2026 · NCT07654361Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention
- Boise VA Medical Center, Boise
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT06390345Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.